This research develops peptide-based drug delivery systems to improve cancer treatment targeting. Unlike conventional therapies, peptides can selectively bind tumors, reducing systemic side effects. Using AI to design high-affinity sequences, the system enhances precision delivery and efficacy, demonstrated by reduced tumor growth in vivo compared to non-targeted treatments.

Genetic cardiomyopathies arise from DNA errors that disrupt vital heart proteins and can be fatal in childhood. This research improves heart-targeted gene therapy by guiding treatments through the bloodstream using chemokine “traffic signals” and avoiding immune interference, enabling therapies to reach the heart more efficiently and potentially cure inherited heart disease.